Response to Ra-223-dichloride in castration-resistant prostate cancer with bone metastasis: A case report

Autor: Cabrera, ME, Rey, PM, Carrio, I, Montes, A, Lopez, DA

Publikováno v: Oncology Letters
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Painful bone metastases are common in prostate cancer, with current treatments including non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone-targeting beta-emitting radiopharmaceuticals. The a-emitting isotope Ra-223-di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3b50c3a81474f422b475ed47f3852411
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7151

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study.

Autor: Lindskog M; Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala University, Uppsala, Sweden., Laurell A; Department of Oncology, Akademiska University Hospital, Uppsala, Sweden., Kjellman A; Department of Urology, CLINTEC, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden., Melichar B; Department of Urology and Urological Oncology, Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego, Lublin, Poland., Rey PM; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Zieliński H; Clinical Urology, Military Institute of Medicine, Warsaw, Poland., Villacampa F; Urology Service, Hospital Unversitario 12 Octubre, Madrid, Spain., Bigot P; Department of Urology, Centre Hospitalier Universitaire d'Angers, Angers Cedex, France., Zoltan B; Szent-Györgyi Albert Klinikai Központ, Szegedi Tudomanyegyetem Altalanos Ovostudomanyi Kar Urologiai Klinika, Szeged, Hungary., Parikh O; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK., Alba DV; Servicio de Urología, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Jellvert Å; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Flaskó T; Department of Urology, Medical School, University of Debrecen, Debrecen, Hungary., Gallardo E; Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain., Caparrós MJR; Department of Urology, Hospital Clínic Barcelona, Barcelona, Spain., Purkalne G; Oncology Clinic, Pauls Stradins Clinical University Hospital, Rīga, Latvia., Suenaert P; Immunicum AB, Stockholm, Sweden., Karlsson-Parra A; Immunicum AB, Stockholm, Sweden.; Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden., Ljungberg B; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Publikováno v: European urology open science [Eur Urol Open Sci] 2022 Apr 26; Vol. 40, pp. 38-45. Date of Electronic Publication: 2022 Apr 26 (Print Publication: 2022).

Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.

Autor: Rey PM; Department of Medical Oncology, Sant Pau Hospital, Barcelona, Spain. jmaroto@santpau.es, Villavicencio H

Publikováno v: Oncology [Oncology] 2008; Vol. 74 (3-4), pp. 245-6. Date of Electronic Publication: 2008 Aug 21.